• Rubén Pampín-Sánchez, Cristina Martínez-Mugica-Barbosa, Eva María Fonseca-Aizpuru, Francisco Javier Barbazán-Vázquez, Beatriz Fernández-González, and Loreto Buznego-Súárez.
• Servicio de Farmacia, Hospital Universitario de Cabueñes, Gijón, Spain. Electronic address: pampin_3@hotmail.com.
• Med Clin (Barc). 2023 Feb 10; 160 (3): 113117113-117.

IntroductionThyroid eye disease (TED) is a complex and incompletely understood rare autoimmune disorder.ObjectivesTo analyze the experience and the outcomes obtained with the use of intravenous tocilizumab in the treatment of TED.MethodsA retrospective analysis of adult patients diagnosed with active TED resistant to intravenous corticosteroids treated in a tertiary hospital between May 2012 and May 2021.ResultsEleven patients were included with a mean age of 52±12 (range 35-67) years. Nine patients were female and two were male. Patients received a median of 5±3.2 doses. Twenty out of twenty-four eyes achieved inactivation of TED at week 16. Proptosis response was achieved in 6/8 patients and diplopia response in 3/8 patients. The GO-QOL questionnaire showed clinically significant improvement in 9/11 patients. No serious adverse effects were reported during tocilizumab treatment. One patient required decompressive surgery 15 months after tocilizumab therapy.ConclusionThe results obtained show that the use of tocilizumab in the treatment of this pathology can be a good alternative.Copyright © 2022 Elsevier España, S.L.U. All rights reserved.

16 keywords...

hide…